• Conexeu completed its 12-month P.R.O.O.F preclinical study for the CXU platform, a key milestone ahead of planned entry into injectable medical aesthetics.
• Study met objectives in facial cheek tissue restoration, a 200cc-equivalent large-volume model, and injectability and volumizing benchmarks.
• First regulatory step set as a predicate-based FDA 510(k) submission in wound care, targeting Q1 2027 and a 90-day review goal.
• Strategy positions wound care clearance as the initial commercialization path, intended to support later expansion into aesthetics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-003545), on July 07, 2026, and is solely responsible for the information contained therein.